Therapy for immunoglobulin А-nephropathy: what along with immunosuppression?

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Immunoglobulin-A nephropathy (IgAN) is the most common form of chronic glomerulonephritis in the world. Unlike other glomerulopathies, which are clinically manifested by episodes of nephrotic and/or acute nephritic syndromes, IgAN in most cases has few symptoms, and the decrease in glomerular filtration rate occurs gradually. The basis of IgAN treatment is individually optimized maintenance therapy aimed at correcting blood pressure, reducing proteinuria, eliminating or minimizing the impact of modifiable risk factors for the progression of chronic kidney disease. This review focuses on modern IgAN maintenance therapy, highlighting both traditional and new directions, and provides a critical analysis of their effectiveness.

Full Text

Restricted Access

About the authors

Irina N. Bobkova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: bobkova_i_n@staff.sechenov.ru
Dr. Sci. (Med.), Professor at the Department of Internal, Occupational Diseases and Rheumatology, Institute of Clinical Medicine n.a. N.V. Sklifosovsky Moscow, Russia

Elena S. Kamyshova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: kamyshova_e_s@staff.sechenov.ru
Cand.Sci. (Med.), Associate Professor at the Department of Internal, Occupational Diseases and Rheumatology, Institute of Clinical Medicine n.a. N.V. Sklifosovsky Moscow, Russia

References

  1. Schena F.P., Nistor I. Epidemiology of IgA Nephropathy: A Global Perspective. Semin. Nephrol. 2018;38(5):435-42. doi: 10.1016/j.semnephrol.2018.05.013.
  2. Feehally J., Cameron J.S. IgA nephropathy: progress before and since Berger. Am. J. Kidney Dis. 2011;58(2):310-9. doi: 10.1053/j.ajkd.2011.03.024.
  3. Floege J., Rauen T., Tang S.C.W. Current treatment of IgA nephropathy. Semin. Immunopathol. 2021;43(5):717-28. doi: 10.1007/s00281-021-00888-3.
  4. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1-276.
  5. Клинические рекомендации «Гломерулярные болезни: иммуноглобулин А нефропатия» 2021 г. Национальная Ассоциация Нефрологов. https://rusnephrology.org/wp-content/uploads/2021/04/iga_060421-1.pdf.
  6. Huang X., Xu G. An Update on Targeted Treatment of IgA Nephropathy: An Autoimmune Perspective. Front. Pharmacol. 2021;12:715253. doi: 10.3389/ fphar.2021.715.
  7. Гуляев С.В., Стрижаков Л.А., Чеботарева Н.В., Моисеев С.В. Роль MALT-системы кишечника в патогенезе IgA-нефропатии. Тер. архив. 2021;93(6):724-8. doi: 10.26442/00403660.2021.06.200868. @@Guliaev S.V., Strizhakov L.A., Chebotareva N.V., Moiseev S.V. Ter. Arkh. 2021;93(6): 724-8. Published 2021 Jun 15. (In Russ.)
  8. Nishiyama A., Konishi Y., Ohashi N., et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol. Dial. Transplant. 2011;26(1):170-7. doi: 10.1093/ndt/gfq371.
  9. Stefanski A., Schmidt K.G., Waldherr R., Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int. 1996;50(4):1321-6. doi: 10.1038/ki.1996.444.
  10. Reich H.N., Troyanov S., Scholey J.W., Cattran D.C; Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. J. Am. Soc. Nephrol. 2007;18(12):3177-83. doi: 10.1681/ ASN.2007050526.
  11. Praga M., Gutierrez E., Gonzalez E., et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J. Am. Soc. Nephrol. 2003;14(6):1578-83. doi: 10.1097/01.asn.0000068460.37369.dc.
  12. Li P.K., Leung C.B., Chow K.M., et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am. J. Kidney Dis. 2006;47(5):751-60. doi: 10.1053/j.ajkd.2006.01.017.
  13. Le W, Liang S., Hu Y., et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol. Dial. Transplant. 2012;27(4):1479-85. doi: 10.1093/ndt/gfr527.
  14. Kanno Y., Okada H., Saruta T., et al. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin. Nephrol. 2000;54:360-5.
  15. Russo D., Pisani A., Balletta M.M., et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am. J. Kidney Dis. 1999;33(5):851-6. doi: 10.1016/ s0272-6386(99)70416-6.
  16. Russo D., Minutolo R., Pisani A., et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J. Kidney Dis. 2001;38(1):18-25. doi: 10.1053/ajkd.2001.25176.
  17. Lennartz D.P., Seikrit C., Wied S., et al. Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy. J. Nephrol. 2020;33(6):1231-9. doi: 10.1007/s40620-020-00836-8.
  18. Tang S.C., Lin M., Tam S., et al. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol. Dial. Transplant. 2012;27(2):613-8. doi: 10.1093/ndt/gfr349.
  19. Szeto C.C., Kwan B.C., Chow K.M., et al. The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy-- a randomized cross-over study. PLoS One. 2013;8(5):e62736. Published 2013 May 10. doi: 10.1371/journal.pone.0062736.
  20. Heerspink H.J., Perkins B.A., Fitchett D.H., et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887
  21. Cherney D.Z.I., Dekkers C.C.J., Barbour S.J., et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial [published correction appears in Lancet Diabetes Endocrinol. 2020 Jun 25]. Lancet Diab. Endocrinol. 2020;8(7):582-93. doi: 10.1016/ S2213-8587(20)30162-5.
  22. Wheeler D.C., Toto R.D., Stefansson B.V., et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1): 215-24. doi: 10.1016/j.kint.2021.03.033.
  23. Barratt J., Floege J. SGLT-2 inhibition in IgA nephropathy: the new standard of care? Kidney Int. 2021;100(1):24-6. doi: 10.1016/j.kint.2021.04.002.
  24. Herrington W.G., Staplin N., Wanner C., et al., EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2022 Nov 4. doi: 10.1056/NEJMoa2204233.
  25. Grande J.P., Donadio J.V. Dietary fish oil supplementation in IgA nephropathy: a therapy in search of a mechanism? Nutrit. 1998;14(2):240-2. doi: 10.1016/s0899-9007(97)00437-1.
  26. Donadio J.V., Bergstralh E.J., Offord K.P., et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N. Engl. J. Med. 1994;331(18):1194-9. doi: 10.1056/NEJM199411033311804
  27. Donadio J.V., Grande J.P, Bergstralh E.J., et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J. Am. Soc. Nephrol. 1999;10(8):1772-7. doi: 10.1681/ASN.V1081772
  28. Hogg R.J, Lee J., Nardelli N., et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin. J. Am. Soc. Nephrol. 2006;1(3):467-74. doi: 10.2215/CJN.01020905.
  29. Strippoli G.F., Manno C, Schena F.P. An "evidence-based"survey of therapeutic options for IgA nephropathy: assessment and criticism. Am. J. Kidney Dis. 2003;41(6):1129-39. doi: 10.1016/s0272-6386(03)00344-5.
  30. Taji Y., Kuwahara T., Shikata S., Morimoto T. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin. Exp. Nephrol. 2006;10(4):268-73. doi: 10.1007/s10157-006-0433-8.
  31. Liu X.J., Geng Y.Q., Xin S.N., et al. Antithrombotic drug therapy for IgA nephropathy: a meta analysis of randomized controlled trials.Intern. Med. 2011;50(21):2503-10. doi: 10.2169/internalmedicine.50.5971.
  32. Kuo K.L., Hung S.C., Tseng W.C., et al. Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease. Oncotarget. 2017;9(4):5368- 77. [Published 2017Aug 3]. doi: 10.18632/oncotarget.19850.
  33. Harabuchi Y, Takahara M. Recent advances in the immunological understanding of association between tonsil and immunoglobulin A nephropathy as a tonsil-induced autoimmune/inflammatory syndrome. Immun. Inflamm. Dis. 2019;7(2):86-93. doi: 10.1002/iid3.248.
  34. Hotta O, Miyazaki M., Furuta T., et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy Am. J. Kidney Dis. 2001;38(4):736-43. doi: 10.1053/ajkd.2001.27690.
  35. Xie Y, Nishi S., Ueno M., et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003;63(5):1861-7. doi: 10.1046/j.1523-1755.2003.00935.x.
  36. Hirano K., Matsuzaki K., Yasuda T., et al. Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy. JAMA.Netw. Open. 2019;2(5):e194772. [Published 2019 May 3]. doi: 10.1001/ jamanetworkopen.2019.4772.
  37. Duan J., Liu D., Duan G., Liu Z. Long term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta-analysis.Int. Urol. Nephrol. 2017;49(1):103-12. doi: 10.1007/s11255-016-1432-7.
  38. Rasche F.M., Schwarz A., Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin. Nephrol. 1999;51:147-52.
  39. Piccoli A., Codognotto M., Tabbi M.G., et al. Influence of tonsillectomy on the progression of mesangioproliferative glomerulonephritis. Nephrol. Dial. Transplant. 2010;25(8):2583-9. doi: 10.1093/ndt/gfq107.
  40. Kovacs T., Vas T., Kovesdy C.P., et al. Effect of tonsillectomy and its timing on renal outcomes in Caucasian IgA nephropathy patients.Int. Urol. Nephrol. 2014;46(11):2175-82. doi: 10.1007/s11255-014-0818-7.
  41. Liu L.L., Wang L.N., Jiang Y., et al. Tonsillectomy for IgA Nephropathy: a meta-analysis. Am. J. Kidney Dis. 2015;65(1):80-7. doi: 10.1053/j.ajkd.2014.06.036.
  42. Komatsu H., Fujimoto S., Hara S., et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin. J. Am. Soc. Nephrol. 2008;3(5):1301-7. doi: 10.2215/CJN.00310108.
  43. Wang Y., Chen J., Wang Y., et al. A meta-analysis of the clinical remission rate and long-term efficacy of tonsillectomy in patients with IgA nephropathy. Nephrol. Dial. Transplant. 2011;26(6):1923-31. doi: 10.1093/ndt/gfq674.
  44. Добронравов В.А., Кочоян З.Ш., Мужецкая Т.О., Лин Д.И. Анализ эффективности терапии иммуноглобулин А нефропатии. Тер. архив 2020;92(6):23-32. doi: 10.26442/00403660.2020.06.000669. @@Dobronravov V.A., Kochoyan Z.S., Muzhetskaya T.O., Lin D.I. Ter. Arkh. 2020;92(6):23-Published 2020 Jul 9 (I Russ.)
  45. Aratani S., Matsunobu T., Shimizu A., et al. Tonsillectomy Combined With Steroid Pulse Therapy Prevents the Progression of Chronic Kidney Disease in Patients With Immunoglobulin A (IgA) Nephropathy in a Single Japanese Institution. Cureus 2021;13(6):e15736. doi: 10.7759/cureus.157.
  46. Kawamura T., Yoshimura M., Miyazaki Y., et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol. Dial. Transplant. 2014;29(8):1546-53. doi: 10.1093/ndt/gfu020.
  47. Coppo R. The gut-renal connection in IgA nephropathy. Semin. Nephrol. 2018;38:504-12. https://doi.org/10.1016/j.semnephrol.2018.05.020.
  48. De Angelis M., Montemurno E., Piccolo M., et al. (2014) Microbiota and Metabolome Associated with Immunoglobulin A Nephropathy (IgAN). PLoS ONE. 2014;9(6):e99006. doi: 10.1371/journal.pone.0099006.
  49. Lauriero G., Abbad L., Vacca M. et al. Fecal Microbiota Transplantation Modulates Renal Phenotype in the Humanized Mouse Model of IgA Nephropathy. Front. Immunol. 2021;12:694787. doi: 10.3389/fimmu.2021.694787.
  50. Zhao J., Bai M., Yang X., et al. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports. Renal. Failure. 2021;43(1):928-33. doi: 10.1080/0886022X.2021.1936038.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies